We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
P9‐28: A comparison of clinical characteristics, between severe asthmatics who continued omalizumab administration and those underwent switch to other biologic agents.
- Abstract
1 Kyoto University, Japan, 2 Kindai University, Japan B Background and Aims b : Omalizumab (OML) improves severe asthma control and might have an advantage in light of cost-effectiveness, if patients are controlled with lower doses. Patients who continued OML after its administration during the observational period were defined as "C-OML", while patients who were switched from OML to other biologics were defined as "S-OML". B Conclusions b : Severe asthmatics with obesity, allergic rhinitis, low exhaled NO with moderate eosinophilic inflammation may be a good candidate for OML treatment, without requiring high dose of OML.
- Subjects
BIOLOGICALS; ASTHMATICS; OMALIZUMAB; PULMONARY function tests
- Publication
Respirology, 2021, Vol 26, p373
- ISSN
1323-7799
- Publication type
Article
- DOI
10.1111/resp.14150_729